Clinical trials located in

Gdynia

Gdynia city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Gdynia, a vibrant city on Poland’s Baltic coast, is part of the Tricity metropolitan area. Established as a village, it underwent rapid development in the 20th century, becoming a significant seaport by 1926. Unique for its modernist architecture, Gdynia hosts the Gdynia Film Festival, Poland’s premier film event. The city is also home to the ORP Błyskawica, the oldest preserved destroyer in the world, and the Dar Pomorza, a famed tall ship. Gdynia’s picturesque seafront, bustling with cafes and shops, complements its rich maritime heritage.

  • CT-EU-00121743

    Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • Study of Palazestrant or standard therapy in advanced ER+/HER2- breast cancer

    This clinical trial is for patients with advanced or metastatic breast cancer with hyperactivity of estrogen receptors (ER+) and no hyperactivity of HER2- receptors (advanced HER2- breast cancer). The therapy used in the study includes a new drug called palazestrant (OP-1250) and other standard endocrine therapies such as Fulvestrant or aromatase inhibitors (anastrozole, letrozole, exemestane).

    The aim of the study is to compare the effectiveness and safety of palazestrant (OP-1250) as monotherapy compared to the above-mentioned standard therapies in the treatment of this type of breast cancer.

    Patients in the study will be randomly assigned to one of the groups – one receiving palazestrant (OP-1250) and the other receiving one of the standard therapies (fulvestrant, anastrozole, letrozole or exemestane). The study will assess progression-free survival (the time from the start of treatment to the time the disease starts to progress again) and overall survival of participants (the time from the start of treatment to death from any cause).

    • Palazestrant
    • Fulvestrant
    • Anastrozole
    • Letrozole
    • Exemestane
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    • Rilzabrutinib
  • Safety study of tafasitamab with lenalidomide for Diffuse Large B-Cell Lymphoma patients

    In this study, a novel approach to the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) is being investigated. This type of cancer may have either recurred or not responded to previous treatments. The experimental intervention involves the use of two drugs: Tafasitamab, administered intravenously, and Lenalidomide, a oral medication. The study is focused on individuals who have undergone one to three prior treatments and are currently ineligible for intensive chemotherapy or a stem-cell transplant. The study is conducted in an open format, providing transparency regarding the substances being tested. Regular monitoring will be implemented to detect any potential issues and assess the concentration of the medications in participants’ blood.

    • Tafasitamab
    • Lenalidomide
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Study of vaccine combinations against Escherichia coli

    This clinical study is for two vaccines, one protects against a type of bacteria called Escherichia coli (ExPEC9V) and the other is a high-strength flu vaccine. The investigation seeks to determine the effectiveness of administering both vaccines simultaneously compared to separate administrations. The assessment will focus on evaluating immune responses to understand how the body reacts to the vaccines. Additionally, the study aims to identify potential side effects, both at the injection site and elsewhere in the body, caused by the vaccines. Following the administration of shots, participants are required to document any reactions in a diary for 14 days. Subsequent follow-up visits, scheduled 29 days after each shot, will involve repeating tests to assess immune response and reporting any new side effects. The primary interest lies in identifying whether there were any hospital visits related to side effects.

    • HD quadrivalent influenza vaccine
    • ExPEC9V
  • Testing relacorilant and nab-paclitaxel for various types of cancer

    The study is being conducted to investigate a new treatment for advanced ovarian, peritoneal, or fallopian tube cancer that has been unresponsive to standard treatment. The focus is on assessing whether a specific combination of drugs (Relacorilant and Nab-Paclitaxel) is more effective than using Nab-Paclitaxel alone. The primary objective is to determine if this combination can prolong the period before cancer progression without causing excessive side effects, in comparison to the use of Nab-Paclitaxel alone. Another goal is to evaluate whether the treatment can lead to a reduction in the size of the cancer and prevent further progression for an extended duration. Patients will undergo regular assessments to monitor disease progression and survival. Criteria such as RECIST, a measurement system, and a blood test checking for the presence of CA-125, a substance elevated in cancer patients, will be employed to assess disease progress.

    • Relacorilant
    • Nab-paclitaxel
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    • Ozanimod
  • Trial for advanced prostate cancer: combining new drug Fuzuloparib with standard therapy

    This trial is a large, carefully planned test that aims to measure how well a new treatment for prostate cancer works. The treatment uses a medicine called Fuzuloparib, paired with other known medications, Abiraterone Acetate and Prednisone (together callled AA-P). It will be compared against a placebo—a substance that looks identical but doesn’t include the active drug—combined with AA-P. The particular type of cancer this trial is working on is a very challenging one that has spread in the body and resisted traditional hormonal treatments. The study will carefully check how well the cancer responds to the treatment and how the patients feel during the treatment, looking for signs of improvement or any side effects.

    • Abiraterone
    • Fuzuloparib
    • Prednisone
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study of lanifibranor treatment in adults with nonalcoholic fatty liver disease

    This study is a two-part trial looking at how well a drug called Lanifibranor works for adults suffering from liver diseases known as NASH and fibrosis stages F2 and F3. In the first part of the trial, the researchers will compare the effects of Lanifibranor with a placebo, which is a substance with no medical effect. The researchers will be looking at how much the drug can improve the health of the liver. The second part of the study will continue the use of Lanifibranor to see if there are any long-term safety issues. Apart from studying the drug’s effectiveness in resolving NASH and reducing live fibrosis, the trial will also be observing how it affects other aspects of liver health, diabetes, blood sugar and fat levels, liver stiffness and patients’ quality of life.

    • Lanifibranor
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    • Apalutamide
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    • Irinotecan
    • topotecan
    • Lurbinectedin
  • Study of AZD5305 and drug combinations for patients with advanced cancers

    This study concerns several types of advanced solid tumors, including ovarian, breast, pancreatic, prostate, non-small cell lung, colorectal, bladder, gastric, biliary, cervical, and endometrial cancers, as well as small cell lung cancer. The therapy involves the experimental drug AZD5305, which is a type of PARP inhibitor. A PARP inhibitor is a substance that blocks an enzyme (PARP) used by cells to repair damage to their DNA. Blocking PARP can help prevent cancer cells from repairing their damaged DNA, leading to cell death.

    The study will test AZD5305 alone and in combination with other anti-cancer agents, including Paclitaxel, Carboplatin, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd), and Camizestrant.

    The purpose of the study is to determine if AZD5305, alone or with these other drugs, is safe, tolerable, and effective in treating patients with these types of cancer.

    Patients will receive AZD5305 either as monotherapy (on its own) or alongside the specified anti-cancer agents in different modules of the study. Some modules will include dose-escalation parts to find the best dose with the least side effects, followed by expansion parts to further test the effectiveness.

    Each module will look at how well the treatment works and track any side effects that occur, with a special focus on serious or unusual side effects. This study aims to provide new insights into the effectiveness of combination therapies involving AZD5305 for individuals with advanced solid tumors.

    • trastuzumab deruxtecan
    • Saruparib
    • camizestrant
    • Dato-DXd
    • Carboplatin
    • Paclitaxel

See more clinical trials in other cities in Poland:

.